Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

\xe2\x80\x9cWe have made great strides to advance our pipeline programs in 2021 with the first patients dosed in both the Phase 2 TENACITY trial in triple negative breast cancer and the Phase 1 combination trial with Novartis in multiple myeloma.